Binding studies of the anti-retroviral drug, efavirenz to calf thymus DNA using spectroscopic and voltammetric techniques

Marzieh Sadeghi, a* Maryam Bayat, a Shekofeh Cheraghi, a Khirollah Yari, b Rouhollah Heydari, c Sara Dehdashtian a and Mojtaba Shamsipura

ABSTRACT: Interactions between efavirenz (EFZ) with calf thymus DNA (CT-DNA) were investigated in vitro under stimulated physiological conditions using multispectroscopic techniques, cyclic voltammetry viscosity measurement, and gel electrophoresis. Methylene blue and acridine orange dyes were used as spectral probes by fluorescence spectroscopy. Hypochromicity was observed in ultra-violet (UV) absorption band of EFZ. Considerable fluorescence enhancement of EFZ was observed in the presence of increasing amounts of DNA solution and the binding constants (Kf) and corresponding numbers of binding sites (n) were calculated at different temperatures. Thermodynamic parameters including enthalpy change (ΔH) and entropy change (ΔS) were calculated to be −304.78 kJ mol−1 and −924.52 J mol−1 K−1 according to the van’t Hoff equation, which indicated that reaction is predominantly enthalpically driven. In addition, UV/vis absorption titration of DNA bases confirmed that EFZ interacted with guanine and cytosine preferentially. Gel electrophoresis of DNA with EFZ demonstrated that EFZ also has the ability to cleave supercoiled plasmid DNA. Circular dichroism study showed stabilization of the right-handed B form of CT-DNA. All results suggest that EFZ interacts with CT-DNA via an intercalative mode of binding. Copyright © 2015 John Wiley & Sons, Ltd.

RESEARCH HIGHLIGHTS:
• The interaction of efavirenz as an anticancer and anti-retroviral drug with calf thymus DNA (CT-DNA) was studied using multispectroscopic methods combined with cyclic voltammetry.
• Hydrogen bonds and van der Waals forces play main roles in the binding of efavirenz to CT-DNA.
• The drug interacted with DNA in an intercalating mode with a binding constant of 3.50 (± 0.06) × 10^4 mol−1 L.

Keywords: efavirenz; dna interaction; intercalation

Introduction

Efavirenz (EFZ), (S)-6-chloro-4(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one (Fig. 1), is an anti-human immunodeficiency virus (anti-HIV) agent. EFZ is a non-nucleoside reverse-transcriptase inhibitor (NNRTI) used in the treatment of patients with HIV infection (1). EFZ is used in combination with either protease inhibitors (PIs) or nucleoside reverse-transcriptase inhibitors (NRTIs) (2). NNRTIs of HIV-1 have recently received a lot of attention. These drugs stop HIV from multiplying by preventing the RT enzyme from working. This enzyme transcribes HIV genetic material (single-stranded RNA) into double-stranded DNA. This step has to occur before the HIV genetic code gets inserted into the genetic code of an infected cell. EFZ is also used in combination with other anti-retroviral agents as part of an expanded post-exposure prophylaxis regimen to reduce the hazard of HIV infection in people exposed to a significant risk (e.g. needlestick injuries, certain types of unprotected sex etc.). Current guidelines for the management of HIV patients suggest the use of two NRTIs, such as lamivudine and zidovudine, in combination with a NNRTI, such as EFZ (3).

DNA is an important genetic substance of life that carries most of the hereditary information and facilitates the biological synthesis of proteins and enzymes through the replication and transcription of this information (4). DNA has been defined as a primary target molecule for most anti-cancer and antiviral therapies according to cell biologists. Therefore, investigations of interactions of DNA with small molecules are vital for the design of new types of pharmaceutical molecules (5,6). It is well known that small molecules can interact with the DNA double helix through three dominant modes (7): first, intercalative binding, in which the molecules intercalate within the DNA base pairs, which would distort the DNA
strands by unwinding of the double helix; second, electrostatic binding between the negatively charged DNA phosphate backbone and cationic or positive end of the molecules; and third, groove binding involving van der Waal’s interactions in the deep major groove or the shallow minor groove of the DNA helix, which prevent DNA replication to defend against disease (8,9).

One approach to accelerate the availability of new drugs is to reposition drugs approved for other indications as anti-cancer agents (10,11). Recently, Sahabadi et al. reported the interaction of some anti-viral drugs with DNA (10–12). In this context, we studied the interaction of the anti-viral drug, EFZ (Fig. 1) with calf thymus DNA. In this work, the in vitro interaction between EFZ and calf thymus DNA (CT-DNA) was investigated under simulated physiological conditions using UV–vis absorption, fluorescence and circular dichroism (CD) spectroscopy, cyclic voltammetry, as well as DNA melting temperature and viscosity measurements. Acridine orange (AO) and methylene blue (MB) as DNA probes were used for a comparative study of the binding affinity of EFZ to the DNA helix, and its interaction mechanisms were also discussed. The drug binding mode and thermodynamic characteristic were explored. Interaction of EFZ with plasmid circular DNA (pUC18) employing gel electrophoresis was also demonstrated.

The results provide useful insights into drug–DNA interactions, which are valuable for the rational design of drugs that are more efficient as well as understanding the binding mechanism of these drugs with specific DNA sequences.

### Experimental

#### Materials and methods

Highly polymerized CT-DNA, EFZ, AO and HEPES were purchased from Sigma. DNA bases [adenine (A), thymine (T), guanine (G) and cytosine (C)], AO and MB were purchased from Merck. All solutions were prepared using deionized Milli-Q water. HEPES buffer solution was prepared from 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid and the pH was adjusted to 7.4.

The stock solution of DNA was prepared by dissolving DNA in a mixture of Tris (pH 8), EDTA (10 mM), and EDTA (10 mM) buffer solution was prepared from 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid and the pH was adjusted to 7.4.

**Materials and methods**

Highly polymerized CT-DNA, EFZ, AO and HEPES were purchased from Sigma. DNA bases [adenine (A), thymine (T), guanine (G) and cytosine (C)], AO and MB were purchased from Merck. All solutions were prepared using deionized Milli-Q water. HEPES buffer solution was prepared from 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid and the pH was adjusted to 7.4. The stock solution of DNA was prepared by dissolving DNA in a mixture of Tris (pH 8), EDTA (10 mM), and EDTA (10 mM) buffer solution was prepared from 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid and the pH was adjusted to 7.4.

The concentration of DNA solution was expressed in monomer units, which were determined by spectrophotometry at 260 nm using an extinction coefficient (εDNA) of 6600 mol⁻¹L⁻¹cm⁻¹ (13). The stock solution was stored at 4°C. A solution of DNA absorbance at 260 and 280 nm, A260/A280 more than 1.8, indicating that DNA was sufficiently free from protein (14). MB and AO dye stock solutions (1.0 × 10⁻⁴ mol L⁻¹) were prepared by dissolving in HEPES (pH 7.4) buffer and diluting to their required volume. An EFZ stock solution (1.0 × 10⁻⁵ mol L⁻¹) was prepared daily by dissolving an appropriate amount of compound in HEPES buffer.

**Instrumentation**

The UV–vis spectra for DNA–EFZ interactions were obtained using an Agilent 8453 spectrophotometer. Solutions of DNA and EFZ were scanned in a 1-cm quartz cuvette. Absorbance experiments were carried out by keeping the concentration of EFZ constant (5.0 × 10⁻⁵ mol L⁻¹) while varying the DNA concentration from 0 to 1.5 × 10⁻⁴ mol L⁻¹. Absorbance values were recorded after each successive addition of DNA solution and equilibration. Our experiments for determining the melting temperature were carried out for CT-DNA in the absence and presence of different amounts of drug. The melting plot of DNA (5.0 × 10⁻⁵ mol L⁻¹) was monitored by plotting the UV maximum absorption of DNA at 260 nm versus temperature.

Fluorescence intensities were measured using a JASCO spectrofluorimeter (FP 6200) by keeping the concentration of drug constant while varying the DNA concentration from 0.0 to 14 × 10⁻⁵ mol L⁻¹ at three different temperatures (298, 303, or 310 K). In the competitive binding studies, the fluorescence spectra of DNA–AO and DNA–MB complex and the mixture of different concentrations of EFZ to DNA–AO and DNA–MB complex were measured under pH 7.4 HEPES buffer, respectively.

Iodide quenching experiments were conducted by adding stoichiometric small aliquots of potassium iodide stock solution (0.01 mol L⁻¹) to EFZ and EFZ–DNA complex solutions, respectively. The fluorescence intensity was recorded, and then the quenching constants were calculated (6).

CD measurements were recorded on a JASCO (J-810) spectropolarimeter, keeping the concentration of DNA constant (5.0 × 10⁻⁵ mol L⁻¹) while varying the concentration of EFZ.

Viscosity measurements were made using a SCHOT viscosimeter (AVS 450), which thermostated at 25 ± 0.5°C by a constant temperature bath. The DNA concentration was fixed at 5.0 × 10⁻⁵ mol L⁻¹ and flow time was measured with a digital stop watch; the relative viscosities of DNA in the presence and absence of EFZ were calculated from the following eqn (1): (15,16)

\[
\frac{\eta}{\eta_0} = \left( \frac{t - t_0}{t_{DNA} - t_0} \right)
\]

where \(t_0\) and \(t_{DNA}\) are the observed flow times of the solvent and DNA, respectively, while \(t\) is the flow times of the EFZ and DNA mixture. Data are presented as (\(\eta/\eta_0\))⁻¹ versus binding ratio \([([EFZ]/[DNA])\]), where \(\eta\) is the viscosity of DNA in the presence of EFZ and \(\eta_0\) is the viscosity of DNA in the absence of EFZ.

Cyclic voltammetric (CV) experiments were performed using the µ–Autolab electrochemical system (Eco-Chemie, Utrecht, The Netherlands) equipped with GPES/FRA 4.9 software coupled with a conventional three-electrode cell. The working electrode was a glassy carbon disc (1.8 mm diameter), the auxiliary electrode was a platinum wire and the reference electrode was a saturated calomel electrode (SCE) (all electrodes were from AZAR Electrode). The surface of the working electrode was polished using a 0.05-mm alumina prior to each experiment and was rinsed with double-distilled water before usage. All experiments were carried out at ambient temperature.

For the gel electrophoresis experiments, Eppendorf microtubes containing mixtures of equal concentrations of pUC18 plasmid DNA and drug samples in Tris–acetate–EDTA (TAE) buffer (pH 8) ([EFZ]/[DNA]) = 0.0, 0.5, 1, 1.5) were incubated in 37°C for 1 h. After this period, 12 μL of the resulting mixture were electrophoresed on a 1% agarose gel containing ethidium bromide (EB). The bands...
on the gel were detected by EB fluorescence (at 366 nm) with gel documentation (Quantum ST4).

Results and discussion

DNA-binding mode and affinity

**UV–vis spectroscopic studies.** UV–vis absorption measurement is an effective method to detect the binding strength and the mode of drug binding with CT-DNA. Binding of EFZ to CT-DNA was studied by the electronic absorption spectral technique. The UV absorption spectra of EFZ were recorded in the absence and presence of DNA. In the ultraviolet region from 220 to 350 nm, EFZ had a strong absorption peak at 247 and a weak peak at 300 nm. In the presence of increasing concentrations of CT-DNA, a hypochromic shift by a slight red shift (3 nm) at 247 nm is observed (Fig. 2a). Figure 2(b) shows that the total absorption of free EFZ and free DNA was greater than the absorption of the EFZ–DNA complex. This result reveals a hypochromism effect that occurred after the interaction of EFZ with DNA. At about 247 nm, the hypochromicity reaches as high as about 30% with a minor bathochromic effect (3 nm). This observation gives good evidence of the intercalation of EFZ through the stacking and interaction of the aromatic rings of the drug and the base pairs of DNA (14,17).

In order to further investigate the intensity of the interaction between EFZ and CT-DNA, the intrinsic binding constant, $K_b$, was calculated from a plot of $[DNA]/(ε_a - ε_f)$ versus $[DNA]$ using eqn (2), (18,19) (Fig. 2a):

$$\frac{[DNA]}{(ε_a - ε_f)} = \frac{[DNA]}{(ε_b - ε_f)} + \frac{1}{K_b (ε_b - ε_f)} \tag{2}$$

where [DNA] is the concentration of DNA, the molar absorption coefficients $ε_a$, $ε_b$ and $ε_f$ represent the apparent absorption coefficient for the EFZ, the extinction coefficient for the EFZ in the fully bound form and the extinction coefficient for the free EFZ, respectively. In particular, $ε_a$ was determined by a calibration curve of the isolated EFZ in an aqueous solution, following Beer’s law. The apparent extinction coefficient, $ε_a$, was determined as the ratio between the observed absorbance ($A_{obs}$) and the drug concentration, $A_{obs}/[EFZ]$. $K_b$ is given by the ratio of slope to the intercept.

The $K_b$ value obtained was $(3.5 \pm 0.06) \times 10^4$ mol$^{-1}$ L. This value indicates a high affinity of the complex for binding to DNA. It is comparable with binding constants of well known intercalating agents such as MB $(2.13 \times 10^4$ mol$^{-1}$ L) and AO $(2.69 \times 10^4$ mol$^{-1}$ L) (14), it seems that EFZ binds strongly to CT-DNA via an intercalation mechanism.

**Thermal denaturation ($T_m$) studies**

Interaction of small molecules with double-stranded DNA can influence the melting temperature ($T_m$), at which the double helix denatures into single-stranded DNA. Thermal denaturation of DNA is a straight forward method to determine the stabilization/destabilization effect of ligands on DNA double helix. The extent of this stabilization also provides a semi-quantitative evaluation of ligand affinity toward DNA duplex (20). On the other hand, the melting of DNA can be used to distinguish between the molecules that induce intercalation and those that bind externally to the biopolymer, respectively. Intercalation of small molecules into the double helix is known to increase the helix melting temperature stabilizing the natural structure of DNA, while the non-intercalative binding causes no obvious variation upon $T_m$ (21).

In the present study, we have used fluorescence studies to monitor the interaction of anti-viral drug EFZ with CT-DNA, and the results were shown in Fig. 4. Under our experimental conditions, an aqueous solution of EFZ exhibits broad fluorescence between 360 and 600 nm with the maximum at around 405 nm when excited at 270 nm.

The fluorescence spectrum of EFZ was markedly affected by the addition of DNA. The emission intensity of EFZ in the presence of DNA is 2 times greater than that in the absence of DNA, with a [DNA]/[EFZ] ratio of two and a red shift of 7 nm. The increase in emission intensity implies that EFZ can insert itself between DNA base pairs. The red shift shows that the EFZ is protected from solvent water molecules by the hydrophobic environment inside the DNA helix.

**Fluorescence spectroscopic studies**

The fluorescence titration experiment has been widely used to characterize the interaction of different drugs with DNA, by following the changes in fluorescence intensity of the drugs. The interactions between the drugs and DNA can prevent the fluorescence emission of the complexes from being quenched by polar solvent molecules and result in the enhancement of fluorescence intensity (22,23).

In the present study, it has been used to monitor the interaction of anti-viral drug EFZ with CT-DNA, and the results were shown in Fig. 4. Under our experimental conditions, an aqueous solution of EFZ exhibits broad fluorescence between 360 and 600 nm with the maximum at around 405 nm when excited at 270 nm.

The fluorescence spectrum of EFZ was markedly affected by the addition of DNA. The emission intensity of EFZ in the presence of DNA is 2 times greater than that in the absence of DNA, with a [DNA]/[EFZ] ratio of two and a red shift of 7 nm. The increase in emission intensity implies that EFZ can insert itself between DNA base pairs. The red shift shows that the EFZ is protected from solvent water molecules by the hydrophobic environment inside the DNA helix.

![Figure 2](https://example.com/figure2.png)

**Figure 2.** (a) Absorption spectra of EFZ (5.0 × 10$^{-5}$ M) in the absence and presence of increasing amounts of DNA, c (DNA) (×10$^{-5}$ mol L$^{-1}$): 0.00, 0.75, 1.75, 2.75, 4.50, 6.50, 7.50, 10.00, 15.00 and 298 K. (b) Comparison of absorption between the DNA–EFZ complex and the sum of values for DNA and EFZ at $λ_{max}$. 

**Figure 3.** Melting plot of DNA (5.0 × 10$^{-5}$ mol L$^{-1}$) was monitored by plotting the UV maximum absorption of DNA at 260 nm versus temperature at various binding ratios (Fig. 3). In the present case, melting temperature ($T_m$) of DNA in the absence of any added drug has been found to be 70 ± 0.5°C. An increase in the DNA melting temperature by 5 and 6°C, for the above-mentioned concentrations were observed. These values clearly show that the EFZ is able to stabilize DNA helix.
DNA helix (6,12,23,24). This marked increase in emission intensity also agrees with findings obtained with other intercalators (25).

Analogous to the quenching constant in a quenching process, the enhancement constant can be obtained from the following equation (12,13):

\[
\frac{F_0}{F} = \frac{1}{C_0} K_D E^{1/2}/C_{138}
\]  

(3)

If a dynamic process is a part of the enhancing mechanism, the above equation can be written as follows (12,26):

\[
\frac{F_0}{F} = \frac{1}{C_0} K_D E^{1/2}/C_{138} = \frac{1}{C_0} K_B \tau_0 E^{1/2}/C_{138}
\]  

(4)

where \(k_D\) is the dynamic enhancement constant (like a dynamic quenching constant), \(K_B\) is the bimolecular enhancement constant and \(\tau_0\) is the lifetime of the fluorophore in the absence of the enhancer. The dynamic enhancement constant of EFZ at different temperatures were calculated using eqn (4) (Table 1 and Fig. 5).

Since fluorescence lifetime is typically near \(10^{-8}\) s, the bimolecular enhancement constant \(K_B\) was calculated from \(K_D = K_B \tau_0\) (Table 1). By considering the equivalency of the bimolecular quenching and enhancement constants, it can be seen that the latter constant \(K_B\) is greater than the largest possible value \((1.0 \times 10^{10}\) mol\(\cdot\)L\(^{-1}\)\(\cdot\)sec\(^{-1}\)) in aqueous medium (12,27). Thus, the fluorescence enhancement is not initiated by a dynamic process, but is instead due to a static process involving ground state complex formation. The possibility for ground state complex formation is supported by observed changes in the absorption spectra during the titration of the drug with CT-DNA, as shown in Fig. 2. Because dynamic quenching only affects the excited state, no changes are expected in the ground state. Alternatively, a static process only involves complex formation in the ground state (13).

**Binding constants and the number of binding sites**

Fluorescence titration data were used to determine the binding constant \(K_f\) and binding stoichiometry \(n\) for the complex formed between EFZ and CT-DNA. Figure 4 shows the fluorescence spectra of EFZ in the presence of different concentrations of CT-DNA. As can be seen from Fig. 4, the fluorescence intensity was increased in the presence of CT-DNA. This change in fluorescence intensity at 405 nm was used to estimate \(K_f\) and \(n\) for the binding of EFZ to CT-DNA from the following equation (28):

\[
\frac{F_0}{F} = \frac{1}{[\text{DNA}] \times 10^5} = \frac{1}{C_0} K_f \times n 
\]

(28)

DNA helix (6,12,23,24). This marked increase in emission intensity also agrees with findings obtained with other intercalators (25).

Analogous to the quenching constant in a quenching process, the enhancement constant can be obtained from the following equation (12,13):

\[
\frac{F_0}{F} = \frac{1}{C_0} K_D [E] 
\]  

(3)

If a dynamic process is a part of the enhancing mechanism, the above equation can be written as follows (12,26):

\[
\frac{F_0}{F} = \frac{1}{C_0} K_D [E] = \frac{1}{C_0} K_B \tau_0 [E] 
\]  

(4)

where \(k_D\) is the dynamic enhancement constant (like a dynamic quenching constant), \(K_B\) is the bimolecular enhancement constant and \(\tau_0\) is the lifetime of the fluorophore in the absence of the enhancer. The dynamic enhancement constant of EFZ at different temperatures were calculated using eqn (4) (Table 1 and Fig. 5).

Since fluorescence lifetime is typically near \(10^{-8}\) s, the bimolecular enhancement constant \(K_B\) was calculated from \(K_D = K_B \tau_0\) (Table 1). By considering the equivalency of the bimolecular quenching and enhancement constants, it can be seen that the latter constant \(K_B\) is greater than the largest possible value \((1.0 \times 10^{10}\) mol\(\cdot\)L\(^{-1}\)\(\cdot\)sec\(^{-1}\)) in aqueous medium (12,27). Thus, the fluorescence enhancement is not initiated by a dynamic process, but is instead due to a static process involving ground state complex formation. The possibility for ground state complex formation is supported by observed changes in the absorption spectra during the titration of the drug with CT-DNA, as shown in Fig. 2. Because dynamic quenching only affects the excited state, no changes are expected in the ground state. Alternatively, a static process only involves complex formation in the ground state (13).

**Table 1.** Dynamic enhancement and biomolecular enhancement constants for interactions between EFZ and CT-DNA at different temperatures

<table>
<thead>
<tr>
<th>Temperature (K)</th>
<th>(R^2)</th>
<th>(K_D)</th>
<th>(K_B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>298</td>
<td>0.99</td>
<td>2270 ± 37 (2.27 ± 0.04) × 10(^{11})</td>
<td></td>
</tr>
<tr>
<td>303</td>
<td>0.99</td>
<td>3085 ± 48 (3.08 ± 0.05) × 10(^{11})</td>
<td></td>
</tr>
<tr>
<td>310</td>
<td>0.99</td>
<td>3671 ± 82 (3.67 ± 0.08) × 10(^{11})</td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Binding constants (Kf) and number of binding sites (n) of the complex–DNA system at different temperatures

<table>
<thead>
<tr>
<th>Temperature (K)</th>
<th>R²</th>
<th>n</th>
<th>Kf (mol⁻¹ L⁻¹)</th>
<th>Log Kf</th>
</tr>
</thead>
<tbody>
<tr>
<td>298</td>
<td>0.99</td>
<td>(1.98 ± 0.07)</td>
<td>(1.15 ± 0.36) × 10⁶</td>
<td>5.06 ± 0.18</td>
</tr>
<tr>
<td>303</td>
<td>0.99</td>
<td>(1.90 ± 0.06)</td>
<td>(2.19 ± 0.10) × 10⁶</td>
<td>4.34 ± 0.16</td>
</tr>
<tr>
<td>310</td>
<td>0.99</td>
<td>(1.81 ± 0.03)</td>
<td>(1.20 ± 0.09) × 10⁶</td>
<td>3.08 ± 0.05</td>
</tr>
</tbody>
</table>

Thermodynamic studies

The interaction forces between drug and biomolecule may involve hydrophobic forces, electrostatic interactions, van der Waals interactions, hydrogen bonds, etc. (30). According to the data of enthalpy changes (ΔH) and entropy changes (ΔS), the model of interaction between drug and biomolecule can be concluded (12,31): (i) ΔH > 0 and ΔS > 0, hydrophobic forces; (ii) ΔH < 0 and ΔS < 0, van der Waals interactions and hydrogen bonds; (iii) ΔH < 0 and ΔS > 0, electrostatic interactions (26). In order to elucidate the interaction of EFZ with DNA, the thermodynamic parameters were calculated. The plot of lnKf versus 1/T (Fig. 6 and eqn (7)) allows the determination of ΔH and ΔS. If the temperature does not vary significantly, the enthalpy change can be regarded as a constant. Based on the binding constant at different temperatures, the free energy change can be estimated (Table 3 and eqn (8)) by the following equations:

\[
\Delta G = \Delta H - T \Delta S
\]

where Kf is the binding constant at the corresponding temperature and R is gas constant. It can be seen that the negative value of ΔG revealed that the interaction process is spontaneous; the negative ΔH and ΔS values indicated that hydrogen bonds and van der Waals forces play main roles in the binding of EFZ to DNA. The presence of electronegative elements in EFZ facilitated its interaction with the DNA molecule through hydrogen bonding with the GC and AT hydrogen (1).

Fluorescence competitive binding studies

Competitive binding between AO and EFZ for DNA. In order to obtain an insight into the binding mode between EFZ and DNA, a competitive binding experiment using AO was performed. AO is a classic intercalating dye (7,32,33). The fluorescence intensity of AO (3.0 × 10⁻⁶ mol L⁻¹) increased after binding with DNA (up to 8.0 × 10⁻⁵ mol L⁻¹), but after addition of more DNA the fluorescence intensity was not enhanced further. The effects of EFZ on the fluorescence spectra of DNA–AO systems were measured. It should be noted that the effect of EFZ on the pure AO spectrum has been carefully checked, and no variation in the fluorescence spectrum was detected. Therefore, if EFZ intercalated into the helix of DNA, it would compete with AO for the intercalation process.

Table 3. Thermodynamic parameters and binding constant for the binding of EFZ to calf thymus DNAΔG°

<table>
<thead>
<tr>
<th>Temperature (K)</th>
<th>Ln Kf (mol⁻¹ L⁻¹)</th>
<th>ΔG° (kJ mol⁻¹)</th>
<th>ΔH° (kJ mol⁻¹)</th>
<th>ΔS° (J mol⁻¹ K⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>298</td>
<td>11.65</td>
<td>-28.99</td>
<td>-304.78 ± 2.60</td>
<td>-924.52 ± 8.90</td>
</tr>
<tr>
<td>303</td>
<td>9.99</td>
<td>-25.17</td>
<td>-304.78 ± 2.60</td>
<td>-924.52 ± 8.90</td>
</tr>
<tr>
<td>310</td>
<td>7.09</td>
<td>-17.96</td>
<td>-304.78 ± 2.60</td>
<td>-924.52 ± 8.90</td>
</tr>
</tbody>
</table>
sites in DNA and lead to a significant decrease in the fluorescence intensity of the AO–DNA complex. By addition of EFZ to the DNA–AO solution, the fluorescence of AO was decreased, suggesting that EFZ could intercalate into the double helix of DNA (Fig. 7).

**Competitive binding between MB and EFZ for DNA.** In order to provide further evidence for the interaction mode, binding of EFZ to CT-DNA has been studied by a competitive binding fluorescence experiment using MB as a probe. MB is a phenothiazinium dye that can interact with DNA by intercalation, and it has been tested using several spectroscopic methods (34–36).

The results revealed that by addition of CT-DNA, the fluorescence of MB (5.0 \times 10^{-6} \text{ mol L}^{-1}) efficiently quenched. MB fluorescence reached minimum after addition of 5.0 \times 10^{-5} \text{ mol L}^{-1} DNA; after addition of more DNA the fluorescence spectrum was constant. This emission-quenching phenomenon is due to the changes in the excited-state electronic structure as a consequence of electronic interactions in the MB–DNA complex (34,37).

The effects of EFZ on the fluorescence spectra of DNA–MB systems were measured. As shown in Fig. 8, the fluorescence intensity of the DNA–MB complex increased with increasing concentrations of EFZ. When EFZ was added directly into the MB solution, the change of MB fluorescence intensity was not observed. This finding indicates that EFZ does not react with MB when DNA is absent. The increase in the fluorescence intensity could be due to a greater amount of free MB molecules; in other words, the MB molecules were released after the addition of EFZ and the fluorescence of the solution was increased. Therefore, the formation of EFZ–DNA prevents the binding of MB. Consequently, recovery of MB fluorescence is indicative of an intercalative mode of binding; this experiment confirms our previous evidence.

**Iodide quenching studies**

Further support for the intercalative binding of efavirenz to DNA was obtained through iodide quenching experiments. It is well known that intercalation of small molecules into DNA double helix stands protects the entrapped molecules from an ionic quencher and consequently, fluorescence quenching of the probe by an ionic quencher is not expected in an intercalated condition (32). By contrast, in electrostatic binding and groove binding, the probe molecules are exposed to the quencher in the aqueous phase, and the fluorescence of the probe molecule should be quenched efficiently (33). Negatively charged I\(^-\) was selected for this purpose. In aqueous solutions, potassium iodide quench the fluorescence of EFV very efficiently, so we used the anionic quencher to determine the relative accessibilities of the free and bound EFV. The quenching constants (KSV) were obtained from Stern–Volmer equation. The values of KSV of EFZ by I\(^-\) ion in the absence and presence of DNA were calculated to be 541.9 and 389.5 \text{ L mol}^{-1}, respectively. (shown in Fig. 9).

The decreases of the quenching constants of KI on EFZ after adding DNA resulted from the intercalative binding of EFZ with the DNA double helix, which prevented fluorescence quenching of EFZ from anionic quenchers because of the sandwich structure formed by EFZ and two DNA base pairs as well as by the polyphosphate anionic skeleton of DNA.

**Circular dichroism spectroscopy**

Circular dichroic spectroscopic techniques give us useful information on how the conformation of DNA is influenced by the binding of the drug to DNA. The changes in CD signals of DNA observed on interaction with drugs may often be assigned to the corresponding changes in DNA structure. The observed CD spectrum of calf
thymus DNA consists of a positive band at 275 nm due to base stacking and a negative band at 245 nm due to helicity, which is characteristic of DNA in the right-handed B form (6,38). Simple groove binding and electrostatic interaction of small molecules with DNA show less or no perturbations on the base stacking and helicity bands, while binding via the intercalation mode in classic intercalators such as MB, causes change in intensities of both the bands and stabilizing the right-handed B conformation of CT-DNA (39). The effect of EFZ on the conformation of the secondary structure of DNA was studied by keeping the concentration of CT-DNA at $5.0 \times 10^{-5}$ mol L$^{-1}$, while varying the concentration of EFZ. The results of CD studies indicated that when the $[\text{EFZ}]/[\text{DNA}]$ ratio was increased, clear changes occurred in the CD spectra. In Fig. 10, the changes in the CD spectrum of CT-DNA in the presence of increasing concentrations of EFZ were depicted. The intensities of negative bands decreased along with a bathochromic effect about 3.0 nm, while the positive bands increased. The positive band showed increase in molar ellipticity without any significant shift in the band maxima when the EFZ concentration was increased progressively.

The changes in the CD spectra may reflect a shift from a B-like DNA structure toward one with some contributions from an A-like conformation (40–42). It has been reported that an enhancement of the CD band of DNA at 275 nm is due to distortions induced in the DNA structure (6). In addition, a red shift in the CD spectra at 245 nm suggested that interactions exist between the aromatic ring of the drug and the DNA base pairs (43). Therefore, we think that the increase in CD signals around 275 nm, along with increasing the EFZ concentration, is important evidence for the intercalation of this anti-viral drug with the DNA base pairs, which concurs with other previously reported data (34,43).

**Binding region**

According to the above discussion, the binding mechanism between EFZ and DNA is an intercalation. The influences of DNA bases, C, G, A and T on the UV/vis absorption spectra of EFZ were used to confirm the binding region of EFZ. Figure 11 reveals the changes in the UV/vis absorption spectra after the addition of different bases to a EFZ solution. The absorption intensity enhanced gradually with the increase in the four types of bases. As shown in Fig. 8, in the vicinity of 250 nm, the binding force of EFZ with C and G is greater than that with A and T. The results suggested that EFZ could interact with the four types of bases, however, the interactive forces of EFZ with C and G were greater than with A and T, and EFZ bound mainly to C–G enriched regions of the DNA, that is intercalative binding.

![Figure 10](image-url)

**Figure 10.** Changes in the CD spectra of $5.0 \times 10^{-5}$ mol L$^{-1}$ DNA in the absence and presence of EFZ; c (EFZ) ($\times 10^{-5}$ mol L$^{-1}$): 0.00, 1.50, 3.50, 6.50, 7.50 and 298 K.

![Figure 11](image-url)

**Figure 11.** UV/vis absorption spectra of EFZ after adding different concentrations of G (a); A (b); T (c); and C (d). [EFZ] = $5.0 \times 10^{-5}$ mol L$^{-1}$; [G] = 0.05 mol L$^{-1}$; [C] = 0.05 mol L$^{-1}$; [A] = 0.05 mol L$^{-1}$; [T] = 0.05 mol L$^{-1}$ (1 μL per scan; 0–8 μL).

---

*Luminescence* 2016; 31: 108–117
Viscosity studies

Optical photophysical probes generally provide necessary, but not sufficient, clues to support binding mode. Hydrodynamic measurements that are sensitive to length change (i.e., viscosity and sedimentation) are regarded as the least ambiguous and the most critical tests of binding in solution in the absence of crystallographic structural data. A classical intercalative mode causes a significant increase in viscosity of DNA due to an increase in separation of base pairs at intercalation sites and hence an increase in overall DNA length occurs. In contrast, a partial, non-classical intercalation of molecule could bend or kink the DNA helix, reducing its length and, concomitantly, its viscosity (44,45).

In addition, molecules that bind exclusively in the DNA grooves by partial and/or non-classical intercalation, under the same conditions, typically cause less pronounced (positive or negative) or no change in DNA solution viscosity (6,46). The values of relative specific viscosity ($\eta/\eta_o)^{1/3}$ versus ($[\text{EFZ}]/[\text{DNA}]$, in the absence and in the presence of EFZ were plotted (Fig. 12). It can be observed that the viscosity of the DNA increases steadily with increasing amounts of EFZ. Such behavior is accordance with other intercalators, and increases the relative specific viscosity for lengthening of the DNA double helix, resulting from intercalation. These results indicate that EFZ can intercalate into the adjacent DNA base pairs, causing an extension in the helix and thus increase the viscosity of DNA (6,12).

Gel electrophoresis

The cleavage of plasmid DNA can be seen by agarose-gel electrophoresis. When circular plasmid DNA is subject to electrophoresis, relatively fast migration is commonly observed for the intact supercoiled Form I. When scission occurs on one strand (nicking), the supercoil relaxes to form a slower moving, open-circular Form II. When both strands are intercepted, a linear Form III is generated that migrates between Form I and Form II DNA (47). In order to assess any devastation of the DNA as a result of binding, EFZ agarose-gel electrophoresis has been performed with the circular form of plasmid DNA. Figure 13 shows gel electrophoresis separation of pUC18 DNA after incubation with EFZ, as well as showing the migration of conversion of Forms I–III after 60 min irradiation in the presence of varying concentrations of EFZ. With increasing concentration of EFZ, the amount of Form I DNA diminishes gradually, whereas that of Form II increases. Line 0 has DNA alone as control line. In lane 4 Form II of plasmid DNA was converted to
Form III, indicating two subsequent and nearby non-random single-stranded breaks in DNA.

Cyclic voltammetry

The application of an electrochemical technique to study the interaction of electroactive compounds with DNA provided a useful complement to the optical techniques. In the present study this technique was employed to understand the nature of DNA binding to EFZ and the results are shown in Fig. 14. As shown in this figure, EFZ presents a well defined oxidation peak at about 0.25 V. This anodic peak can be attributed to the oxidation of the nitrogen atom on the benzoxazine ring (48). In the presence of DNA, the cyclic voltammograms of EFZ exhibited positive shift in the anodic peak potential followed by a decrease in the peak current, indicating the interaction that exists between EFZ and DNA. The decreases in peak current can be explained in terms of slow diffusion of EFZ bound to the large DNA molecules (49), and also support the changes found in CV experiments. Hence it can be concluded that the EFZ molecule binds to DNA via intercalation, with insertion of the EFZ molecule between the base pairs of the DNA duplex strand.

The interaction of EFZ with DNA can be described using eqn (9):

\[ EFZ + DNA \rightarrow EFZ - DNA \]  
(9)

The binding constant, K, of the interaction of EFZ with DNA was determined according to the following equation (10):

\[ \log \left( \frac{1}{[DNA]} \right) = \log (K) + \log \left( \frac{I_{\text{free}}}{I_{\text{free}} - I_{\text{bond}}} \right) \]  
(10)

where K is the apparent binding constant, \( I_{\text{free}} \) and \( I_{\text{bond}} \) the peak current of the free guest and the adduct, respectively. The plot of \( \log(1/[DNA]) \) versus \( \log(I_{\text{free}}/(I_{\text{free}} - I_{\text{bond}})) \) (Fig. 15) becomes linear with the intercept of \( \log(K) \) according to (eqn 10). Binding constants of EFZ and DNA were calculated to be \( 2.40 \pm 0.04 \times 10^4 \) mol\(^{-1}\)L\(^{-1}\) using CV data (eqn 10), which is very similar to that calculated using spectrophotometry data (Table 2).

Conclusion

We have explored the binding interaction of EFZ with CT-DNA in physiological buffer using multispectroscopic techniques, cyclic voltammetry viscosity measurement, and gel electrophoresis. The binding constants of this complex with DNA were measured at different temperatures, and the thermodynamic parameters were calculated. It was found that hydrogen bonds and van der Waals forces play a major role in the binding of EFZ to DNA. The intrinsic binding constant observed (\( K_b = 3.50 \pm 0.06 \times 10^4 \) mol\(^{-1}\)L\(^{-1}\)) was roughly comparable to other intercalators.

The intercalative binding of the drug with DNA (Fig. 16) was deduced by taking account of relevant UV–vis absorption spectra, circular dichroism, fluorescence spectra, iodide quenching effect, cyclic voltammetry and viscosity measurements. CD results showed clear conformational changes in the CT-DNA double helix upon binding with the drug. The increase in the relative viscosity as well as melting temperature (5–6°C) of CT-DNA in the presence of EFZ showed that intercalation must be the predominant form of binding. Also, it was shown that this complex could induce DNA cleavage. This study is expected to provide greater insight into the use of anti-viral drugs as anti-cancer agents.

Acknowledgements

The authors gratefully acknowledge the support of this work by Razi University Research Council.

References